REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
|Articles|February 4, 2022
Daily Medication Pearl: Tavaborole (Kerydin)
Author(s)Saro Arakelians, PharmD
Tavaborole (Kerydin) is indicated for the topical treatment of onychomycosis of the toenails.
Advertisement
Medication Pearl of the Day: Tavaborole (Kerydin)
Indication: Tavaborole (Kerydin) is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes.
Insight:
- Dosing: Apply tavaboroleto affected toenails once daily for 48 weeks.
- Dosage forms:Solution, 5%.
- Adverse events: Common adverse reactions occurring in ≥1% in subjects treated with tavaboroleincluded application site exfoliation, ingrown toenail, application site erythema, and application site dermatitis.
- Mechanism of action: Kerydin is an oxaborole antifungal.
- Manufacturer: Anacor Pharma
Sources:
Advertisement
Related to this article
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
Oncology Pharmacists Reduce Adverse Drug Reactions in Hematologic Cancer Care
4
Recap: Tirzepatide Is Approved to Cut Cardiovascular Risk in Type 2 Diabetes
5